Andrea de Castro González

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (84)

• Data from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.c.8688030
  +Save
• Figure 1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414894
  +Save
• Figure 2 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414891
  +Save
• Figure 3 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414888
  +Save
• Figure 4 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414885
  +Save
• Figure 5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414879
  +Save
• Figure 6 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414876
  +Save
• Figure 7 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414873
  +Save
• Figure S1 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414870
  +Save
• Figure S10 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414867
  +Save
• Figure S11 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414864
  +Save
• Figure S12 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414861
  +Save
• Figure S13 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414858
  +Save
• Figure S14 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414855
  +Save
• Figure S15 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414852
  +Save
• Figure S2 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414849
  +Save
• Figure S3 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414846
  +Save
• Figure S4 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414843
  +Save
• Figure S5 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414840
  +Save
• Figure S6 from KRAS Inhibitor–Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones
  2026 DOI: 10.1158/0008-5472.33414837
  +Save